Literature DB >> 20130374

Multidrug-resistant and extensively drug resistant tuberculosis in Kashmir, India.

Bikram Singh Datta1, Ghulam Hassan, Syed Manzoor Kadri, Waseem Qureshi, Mustadiq Ahmad Kamili, Hardeep Singh, Ahmad Manzoor, Mushtaq Ahmad Wani, Natasha Thakur.   

Abstract

BACKGROUND: To study the profile of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) in tertiary care hospital setting, representing almost the whole affected population in Kashmir valley of India.
METHODOLOGY: A total of 910 cases of pulmonary tuberculosis were enrolled over four years. Among these, cases of MDR-TB and XDR-TB were meticulously studied for drug susceptibility, treatment, adverse effects profile and overall survival.
RESULTS: Fifty-two (5.7%) cases of MDR-TB were identified, among which eight (15.3%) were diagnosed as XDR-TB on the basis of drug susceptibility testing, using the prescribed definition. The cases were sensitive to 2, 3, 4, 5 and more than 5 drugs in almost equal proportions. Thirty-seven (71.1%) cases were successfully cured; eleven (21.1%) patients died; and only four (7.6%) cases defaulted, indicating overall satisfactory adherence to treatment.
CONCLUSION: For effective treatment of MDR-TB and XDR-TB, early case detection, improved laboratory facilities, availability of appropriate treatment regimens, and financial assistance in resource-limited settings through effective political intervention are necessary for better patient adherence and overall cure.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20130374     DOI: 10.3855/jidc.669

Source DB:  PubMed          Journal:  J Infect Dev Ctries        ISSN: 1972-2680            Impact factor:   0.968


  14 in total

1.  First Line Anti-TB Drug Resistance in an Urban Area of Odisha, India.

Authors:  Dasarathi Das; Prakasini Satapathy; Biswanath Murmu
Journal:  J Clin Diagn Res       Date:  2016-11-01

Review 2.  Extensively drug-resistant tuberculosis in India: a review.

Authors:  Joy Sarojini Michael; T Jacob John
Journal:  Indian J Med Res       Date:  2012-10       Impact factor: 2.375

Review 3.  Prevalence of inappropriate tuberculosis treatment regimens: a systematic review.

Authors:  M W Langendam; M J van der Werf; E Huitric; D Manissero
Journal:  Eur Respir J       Date:  2011-10-17       Impact factor: 16.671

4.  Socioepidemiological status and clinical outcome of MDR TB patients in a tertiary medical college in Southern Odisha.

Authors:  Manoranjan Dash; Bibhu Prasad Behera
Journal:  J Family Med Prim Care       Date:  2022-03-18

5.  Loss-To-Follow-Up on Multidrug Resistant Tuberculosis Treatment in Gujarat, India: The WHEN and WHO of It.

Authors:  Kalpita S Shringarpure; Petros Isaakidis; Karuna D Sagili; R K Baxi
Journal:  PLoS One       Date:  2015-07-13       Impact factor: 3.240

Review 6.  Extensively drug-resistant tuberculosis in India: Current evidence on diagnosis & management.

Authors:  Rajendra Prasad; Abhijeet Singh; Viswesvaran Balasubramanian; Nikhil Gupta
Journal:  Indian J Med Res       Date:  2017-03       Impact factor: 2.375

Review 7.  Tuberculosis: From an incurable scourge to a curable disease - journey over a millennium.

Authors:  Surendra K Sharma; Alladi Mohan
Journal:  Indian J Med Res       Date:  2013-03       Impact factor: 2.375

8.  Plumbagin analogs-synthesis, characterization, and antitubercular activity.

Authors:  Nishi Nayak; Meenakshi Bajpai; Balkishen Razdan
Journal:  J Adv Pharm Technol Res       Date:  2014-01

9.  Sputum Smear and Culture Conversion in Multidrug Resistance Tuberculosis Patients in Seven Districts of Central Gujarat, India: A Longitudinal Study.

Authors:  Sangita V Patel; Kapil B Nimavat; Alpesh B Patel; Kedar G Mehta; Kalpita Shringarpure; Lipy K Shukla
Journal:  Indian J Community Med       Date:  2018 Apr-Jun

10.  Profile of drug-resistant tuberculosis in Western Maharashtra.

Authors:  Sudhakar W More; Malangori Abdulgani Parande; Sanjeev W Kamble; Manjunath S Kamble
Journal:  J Family Med Prim Care       Date:  2017 Jan-Mar
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.